CLA Stock Overview
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Akari Therapeutics, Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.51 |
52 Week High | US$4.64 |
52 Week Low | US$0.94 |
Beta | 0.96 |
1 Month Change | 11.03% |
3 Month Change | -35.47% |
1 Year Change | -50.97% |
3 Year Change | -94.86% |
5 Year Change | -97.30% |
Change since IPO | -99.53% |
Recent News & Updates
Recent updates
Shareholder Returns
CLA | DE Biotechs | DE Market | |
---|---|---|---|
7D | 46.6% | 0.8% | -0.5% |
1Y | -51.0% | -21.0% | 2.5% |
Return vs Industry: CLA underperformed the German Biotechs industry which returned -21% over the past year.
Return vs Market: CLA underperformed the German Market which returned 2.5% over the past year.
Price Volatility
CLA volatility | |
---|---|
CLA Average Weekly Movement | 15.2% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CLA's share price has been volatile over the past 3 months.
Volatility Over Time: CLA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 11 | Rachelle Jacques | www.akaritx.com |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
Akari Therapeutics, Plc Fundamentals Summary
CLA fundamental statistics | |
---|---|
Market cap | €10.84m |
Earnings (TTM) | -€9.32m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs CLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$10.01m |
Earnings | -US$10.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.26 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CLA perform over the long term?
See historical performance and comparison